Vigil Neuroscience (NASDAQ:VIGL) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Vigil Neuroscience (NASDAQ:VIGL) announced its earnings results on Thursday. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08), Zacks reports.

Vigil Neuroscience Stock Performance

VIGL opened at $2.16 on Thursday. The firm has a 50 day moving average price of $2.33 and a 200 day moving average price of $2.81. The company has a market cap of $88.30 million, a PE ratio of -1.04 and a beta of 1.82. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. JMP Securities reissued a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research note on Thursday, January 23rd. William Blair started coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vigil Neuroscience presently has a consensus rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.